Manipal Health cuts borrowings after ₹5,310 crore redemption

Manipal Health Enterprises Limited redeemed ₹5,310 crore of non-convertible debentures on September 16, 2026, using proceeds from its ₹8,000 crore fresh equity issue, while consolidated borrowings fell ₹4,805.28 crore to ₹5,748.14 crore at September 30, 2026 from ₹10,553.42 crore at March 31, 2026.

How did Manipal Health use the initial public offering proceeds?

Manipal Health used proceeds from its August 2026 initial public offering, or IPO, to fully redeem ₹5,310 crore of non-convertible debentures, or NCDs, issued by subsidiary Manipal Hospitals Private Limited. The cash-flow statement records ₹8,000 crore of proceeds from the issue of equity shares and ₹5,310 crore of NCD redemptions in the six months ended September 30, 2026.

The IPO comprised a fresh issue of 135,679,811 equity shares worth ₹8,000 crore and an offer for sale of 21,553,904 shares worth ₹1,275 crore by selling shareholders. Manipal Health listed its shares on the National Stock Exchange of India and BSE on August 5, 2026. Only the fresh-issue proceeds were company funds; the filing identifies the NCD repayment as funded from IPO proceeds.

The redeemed instruments had been issued on September 12, 2025 through private placement. They carried a 9.0% annual coupon, payable annually, and were originally redeemable two years after allotment. Their early redemption followed the mandatory redemption event specified in the debenture trust deed, namely Manipal Health's IPO and listing on August 5, 2026.

How much did Manipal Health's borrowings decline?

Manipal Health's consolidated borrowings declined ₹4,805.28 crore, or 45.5%, between March 31, 2026 and September 30, 2026. Non-current borrowings fell ₹4,567.05 crore to ₹5,381.75 crore, while current borrowings decreased ₹238.23 crore to ₹366.39 crore over the same period.

The fall in reported borrowings was smaller than the ₹5,310 crore NCD redemption because financing cash flows also included ₹886.98 crore of proceeds from long-term borrowings during the six-month period. The balance-sheet movement therefore reflects both the debt repayment and subsequent or concurrent borrowing activity, rather than the NCD transaction alone.

The change occurred alongside a ₹8,307.78 crore increase in total equity, which reached ₹17,106.58 crore at September 30, 2026 from ₹8,798.80 crore at March 31, 2026. Equity attributable to Manipal Health's owners rose to ₹16,706.71 crore from ₹8,426.13 crore, while equity share capital rose ₹27.13 crore to ₹263.08 crore.

What was the full cost of redeeming the NCDs?

Manipal Health repaid ₹5,874.45 crore including interest when the NCDs were redeemed, and this amount included a one-time prepayment fee of ₹79.70 crore. The filing classifies that fee as an exceptional item in the quarter ended September 30, 2026, distinguishing it from the principal redemption shown in financing cash flows.

Exceptional items totalled ₹95.18 crore in the September 2026 quarter and ₹110.65 crore in the six months ended September 30, 2026. Apart from the NCD prepayment fee, the filing identifies amortised employee incentive expense of ₹30.95 crore for the six-month period. These items reduced reported profit before tax, which was ₹686.74 crore for the six months ended September 30, 2026, compared with ₹761.98 crore a year earlier.

Finance costs were ₹593.35 crore for the six months ended September 30, 2026, compared with ₹287.68 crore in the corresponding 2025 period. The cash-flow statement separately reports ₹739.65 crore of interest and processing charges paid in the 2026 half year, versus ₹189.19 crore in the earlier period, providing the cash-payment measure alongside the income-statement expense.

What does the cash-flow statement show after the equity issue?

Manipal Health generated ₹1,191.50 crore of net operating cash flow in the six months ended September 30, 2026, up from ₹942.10 crore in the corresponding 2025 period. Operating cash generation was partly offset by ₹1,295.08 crore spent on property, plant and equipment and intangible assets, compared with ₹462.01 crore a year earlier.

Investing cash outflow widened to ₹3,370.71 crore from ₹877.83 crore. The 2026 period included ₹2,172.85 crore invested in bank deposits with original maturity above three months and ₹3,364.35 crore spent purchasing mutual funds and other investments, partly offset by ₹3,302.39 crore of sale proceeds from those investments.

Financing activities generated net cash of ₹2,439.16 crore in the 2026 half year, against ₹5,090.64 crore in the prior-year period. The current-period figure combines the ₹8,000 crore equity inflow, ₹100.74 crore of equity-issue transaction costs, the ₹5,310 crore NCD redemption and ₹739.65 crore of interest and processing charges paid.

Cash and cash equivalents stood at ₹559.31 crore at September 30, 2026, compared with ₹299.36 crore at March 31, 2026. Bank balances other than cash equivalents increased to ₹2,038.26 crore from ₹23.86 crore, while current investments rose to ₹2,637.75 crore from ₹2,392.36 crore, showing that the cash raised and deployed was not all held as cash equivalents at period end.

Conclusion

Manipal Health's September 2026 balance sheet shows a changed funding mix, with the ₹8,000 crore fresh equity issue supporting full repayment of ₹5,310 crore of NCD principal. Total consolidated borrowings ended the period at ₹5,748.14 crore, while the early repayment also produced a ₹79.70 crore one-time fee within ₹110.65 crore of six-month exceptional items.

The next disclosed event to watch is Manipal Health's planned purchase of a further 9.84% stake in Sahyadri Hospitals Private Limited under Tranche 3 on December 1, 2026, subject to conditions in the share purchase agreement. The filing also discloses a subsequent 29-year-and-11-month lease of land in Gurugram for development of a greenfield tertiary-care hospital.